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Aprospective trial conducted in the period 2000-2005 showed no survivaladvantage for high-dose chemotherapy with rituximab and autograft (R-HDS) versus conventional chemotherapy with rituximab (CHOP-R) as first-
line therapy in 134 high-risk follicular lymphoma patients aged <60 years. The
study has been updated at the 13-year median follow up. As of February 2017, 88
(66%) patients were alive, with overall survival of 66.4% at 13 years, without a
significant difference between R-HDS (64.5%) and CHOP-R (68.5%). To date, 46
patients have died, mainly because of disease progression (47.8% of all deaths),
secondary malignancies (3 solid tumor, 9 myelodysplasia/acute leukemia; 26.1%
of all deaths), and other toxicities (21.7% of all deaths). Complete remission was
documented in 98 (73.1%) patients and associated with overall survival, with 13-
year estimates of 77.0% and 36.8% for complete remission versus no-complete
remission, respectively. Molecular remission was documented in 39 (65%) out of
60 evaluable patients and associated with improved survival. In multivariate
analysis, complete remission achievement had the strongest effect on survival
(P<0.001), along with younger age (P=0.002) and female sex (P=0.013). Overall, 50
patients (37.3%) survived with no disease recurrence (18 CHOP-R, 32 R-HDS).
This follow up is the longest reported on follicular lymphoma treated upfront
with rituximab-chemotherapy and demonstrates an unprecedented improvement
in survival compared to the pre-rituximab era, regardless of the use of intensified
or conventional treatment. Complete remission was the most important factor for
prolonged survival and a high proportion of patients had prolonged survival in
their first remission, raising the issue of curability in follicular lymphoma.
(Registered at clinicaltrials.gov identifier: 00435955) 
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ABSTRACT
Introduction
The current first-line treatment strategy for sympto-
matic and advanced follicular lymphoma (FL) is chemo-
immunotherapy, with rituximab in combination with var-
ious chemotherapy regimens.1-2 For a long time now, the
upfront use of intensified chemotherapy with autograft
has been proposed as an effective treatment option for
patients presenting with high-risk disease.3-8 We previous-
ly conducted a prospective randomized trial of these regi-
mens in Italy, including patients <60 years of age who
were affected by high-risk FL. The results showed no sur-
vival advantage from high-dose sequential chemotherapy
with rituximab and autograft (R-HDS) compared to con-
ventional cyclophosphamide, doxorubicin, vincristine,
and prednisone supplemented with rituximab (CHOP-R).9
Despite the limited median follow up of four years, this
observation has discouraged the upfront use of intensive
chemo-immunotherapy with autograft in FL, including in
patients with high-risk disease presentation.
Follicular lymphoma patients now have prolonged life
expectancy, with a median survival of ten years. This sur-
vival rate is possible because of the availability of ritux-
imab along with improvements in the supportive care
instruments.10-13 The increase in patient survival warrants a
long-term update of clinical trials to evaluate the real ben-
efit of any treatment. For this purpose, our previous
results of the randomized R-HDS versus CHOP-R have
been updated by extending the period of analysis to 2017
with a median follow up of 13 years. The prolonged
observation of this prospective cohort of patients offers
the opportunity to define the following in advanced-stage,
high-risk FL patients: (i) the long-term survival following
conventional versus intensified chemotherapy with auto-
graft, both delivered with rituximab; (ii) the main causes
of death; (iii) the main factors affecting long-term out-
come; and (iv) the rate of patients with prolonged survival
in the absence of disease recurrence.
Methods
Patients’ characteristics 
Between March 2000 and May 2005, a total of 136 patients
were enrolled in the multicenter randomized study, launched in
Italy among centers affiliated with Gruppo Italiano Trapianto
Midollo Osseo (GITMO) and/or to the Italian Lymphoma
Intergroup (IIL).9 The institutional review boards of all the partici-
pating centers approved the study. The study was designed for the
first-line treatment of patients aged 16-60 years with a histologi-
cally proven diagnosis of FL.14 Patients were eligible if they had
Ann Arbor stage III or IV and a high-risk prognostic presentation,
according to the prognostic risk scores in use at the time the pro-
tocol was designed, i.e. the age-adjusted International Prognostic
Index (IPI) score >2 and the IIL score >3 for FL.15,16 The CONSORT
Diagram in the Online Supplementary Appendix gives details about
treatment outcome of the 136 enrolled patients. Table 1 describes
the main features of the 134 evaluable patients and the main clin-
ical features of patients who are presently alive versus those who
have died since protocol entry.  
Study design, treatment schedule and end points
The aim of the study was to assess the superiority of an inten-
sive chemo-immunotherapy strategy including autologous
hematopoietic stem cell transplantation (auto-HSCT) compared to
conventional chemo-immunotherapy. A centralized computer
generated a simple randomization sequence and patients were
randomly assigned either to the intensified or conventional arm. 
Both conventional CHOP-R and intensified R-HDS treatments
have already been described.9,17-20 Details of the treatment sched-
ules along with study end points and molecular analysis per-
formed are reported in the Online Supplementary Appendix.9,19,21
Long-term follow up and statistical analysis
The update was made by taking information from 28 out of 29
participating centers regarding the clinical status of each patient
entered in the prospective trial: (i) status alive or dead or lost to fol-
low up, with the date of death or last follow up alive; (ii) cause of
death, i.e. lymphoma progression, secondary neoplasm, non-neo-
plastic late fatal complications, or other causes; (iii) occurrence of
secondary hematopoietic or non-hematopoietic neoplasm; or (iv)
disease status at last follow up alive, i.e. continuous first, second
or more complete remission (CR).
In the present update, alive patients were censored at the date
of last contact (February 2nd, 2017), providing a median event-free
survival (EFS) and overall survival (OS) follow-up time of 13.01
years [range: 0.5-16.6, interquartile range (IQR); 11.8-14.7]. All
analyses were carried out on an intention-to-treat basis. 
Survival curves were estimated by the Kaplan-Meier method
according to the revised response criteria published in 2007, and
compared using the log-rank test.22-24 EFS, OS, progression-free sur-
vival (PFS), and disease-free survival (DFS) were analyzed by the
Cox proportional hazards model, comparing the two treatment
arms (R-CHOP vs. R-HDS) by the Wald test and calculating 95%
Confidence Intervals (CI).25 
The CI of secondary myeloid dysplastic syndrome (sMDS) /
acute myeloid leukemia (AML) and solid malignancies in the
whole cohort and stratified by the treatment arm were estimated
at 5, 10, and 13 years from diagnosis and were assessed by the
Gray test.26 All reported P-values were two-sided, at the conven-
tional 5% significance level. Data were analyzed as of January
2018 using R 3.4.3.27
Results
Overall survival and causes of death
As of February 2017, 88 (66%) patients were alive at
their last follow up. Overall, median survival had not yet
been reached at the 13-year median follow up, with a 13-
year OS estimate of 66.4% for the whole patient cohort.
Similar OS values were observed in the two treatment
arms, with 13-year OS estimates of 68.5% and 64.5% for
patients in the CHOP-R and R-HDS arms, respectively
(Figure 1).
At the latest follow up, 46 patients had died. The main
causes of deaths were disease progression for 22 patients
(16.4% of the whole series, 47.8% of all deaths), second-
ary malignancies (3 solid tumor, 9 sMDS/AML) for 12
patients (8.9% of the whole series, 26.1% of all deaths),
12 patients died of various causes, including six fatal car-
diovascular events, three documented infections, one
graft failure following autograft, one anaphylactic shock
following intravenous immunoglobulin (Ig i.v.) infusion,
and one late sudden death. Among patients in the CHOP-
R arm, 13 of 20 (65%) died from disease-related causes,
whereas lymphoma progression was the cause of death
for 9 of 26 (35%) patients in the R-HDS arm. Main causes
of death per each treatment arm are summarized in
Figure 2. 
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Complete remission and molecular response: 
achievement and durability 
Complete remission was documented in 98 (73.1%)
patients: 39 (59.1%) of 66 undergoing CHOP-R treatment
and 59 (86.7%) of 68 R-HDS-treated patients. CR achieve-
ment had a significantly favorable impact on survival,
with 13-year OS estimates of 77.0% and 36.8%, for CR
versus no-CR achievement, respectively (Figure 3A).
Moreover, a durable CR was associated with prolonged
survival. Overall, of 79 patients in CR at two years since
treatment initiation, 65 (82.3%) were alive at 13 years
compared to 21 (58.3%) among 36 patients with early
relapse (P=0.003). 
Molecular response was documented in 39 (65%) out of
60 evaluable patients: 11 (44%) of 25 undergoing CHOP-
R treatment and 28 (80%) out of 35 R-HDS-treated
patients (P<0.001).9 Again, MR achievement was associat-
ed with a superior OS compared to patients not in MR fol-
lowing treatment (13-year OS estimates of 82.1% and
51.9%, for MR vs. no-MR achievement, respectively)
(Figure 3B). 
13-year update of the R-HDS vs. CHOP-R trial in FL
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Table 1. Main patient features at presentation according to last survival status 
                                                                              All                                     Patients                               Patients                                     P
                                                                          patients                                    alive1                                    dead1                                         
All                                                                                           134                                                   88                                                  46                                                    
M/F                                                                                      78/56                                               45/43                                            33/13                                             0.022
Age (y), median (range)                                                   51                                                    50                                                 53                                               0.297
                                                                                           (22-59)                                           (22-59)                                        (35-59)                                                
Histologic grade I-II,                                                         98                                                     65                                                  33                                                0.792
n. (%)                                                                                  (73)                                                (73)                                             (71)                                                  
age-adjusted IPI 2 or more,                                           120                                                   75                                                  45                                               0.024
n. (%)                                                                                  (89)                                                (85)                                              (98)                                                  
FLIPI 3 or more,                                                                  78                                                    52                                                 26                                               0.775
n.  (%)                                                                                 (58)                                                (59)                                              (56)                                                  
Ann Arbor stage IV, n  (%)                                               118                                                   77                                                 41                                               0.648
                                                                                              (88)                                                (86)                                              (89)                                                  
B symptoms,                                                                        63                                                    40                                                 23                                                0.617
n.  (%)                                                                                 (47)                                                (46)                                             (50)                                                  
ECOG PS 2 or more, n.  (%)                                           80                                                    49                                                 31                                               0.189
                                                                                              (60)                                                (56)                                              (67)                                                  
Bulky disease,                                                                     75                                                    51                                                 24                                               0.522
n. (%)                                                                                  (56)                                                (58)                                              (52)
Spleen involvement,                                                          50                                                    28                                                 22                                               0.061
n. (%)                                                                                  (37)                                                (32)                                              (48)                                                  
Bone marrow involvement,                                             113                                                   72                                                 41                                               0.269
n  (%)                                                                                  (84)                                                (82)                                              (89)                                                  
Extranodal involvement,                                                   42                                                    29                                                 13                                               0.578
n. (%)                                                                                  (31)                                                (33)                                              (28)                                                  
Abnormal LDH,                                                                   65                                                    38                                                  22                                               0.608
n . (%)                                                                                 (59)                                                (43)                                              (48)                                                  
Treatment arm (CHOP-R/R-HDS), n.                          66/68                                               46/42                                            20/26                                             0.371
IPI: International Prognostic Index; FLIPI: follicular lymphoma IPI; n: number; M: male; F: female; ECOG: Eastern Cooperative Oncology Group;  LDH: lactate dehydrogenase. 1Status
after 13 years of median follow up.
Figure 1. Updated overall survival (OS) according to treatment arms. Intensive
chemo-immunotherapy with autograft (R-HDS) versus conventional chemoim-
munotherapy (CHOP-R). Median follow-up: 13 years. No: number; yrs: years.
Overall, 50 patients (37.3% of the whole series) were
alive at this follow up without any disease recurrence (18
in the CHOP-R and 32 in the R-HDS arms) since their first
CR achievement. Among 98 patients obtaining CR, 39 had
disease recurrence (39.8%). In the CHOP-R and R-HDS
arms, the last disease recurrence respectively was record-
ed at ten years and at seven years from CR achievement.
In addition, there were nine late toxic events (1 in CHOP-
R and 9 in R-HDS) in patients in their first continuous CR.
For patients reaching CR, the DFS estimate was 57.9% at
13 years. The 13-year DFS estimate was 47.1% for the 39
patients in CR following CHOP-R and 65.3% for the 59
patients in CR following R-HDS (Figure 4). 
A subgroup of patients was further monitored for their
molecular disease at long-term. After a median of four years
of molecular monitoring since treatment completion, of the
24 patients alive in their first CR and evaluable for molecu-
lar disease, 20 (83%) patients were still in their first MR.   
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Figure 2. Main causes of death in the two treatment arms. Main causes of death include deaths due to: lymphoma, secondary malignancies (3 solid tumor, 9 sec-
ondary myeloid dysplastic syndrome (sMDS) / acute myeloid leukemia (AML)], non-malignant fatal events (6 fatal cardiovascular complications, 3 documented infec-
tions, 1 graft failure following autograft) and other causes (not clearly related to treatment). 
Figure 3. Updated overall survival according to end of treatment clinical status. (A) Complete remission (CR) achievement.  (B)  Molecular remission [polymerase
chain reaction negative (PCR)] achievement. No: number; yrs: years.
A B
The 13-year estimates for EFS and PFS were 37.3% and
46.3% among all patients, respectively. Both EFS and PFS
curves remained significantly superior in the R-HDS com-
pared to CHOP-R arm. For CHOP-R and R-HDS, 13-year
EFS estimates were respectively 26.6% (median EFS: 1.6
years) and 48.5% (median EFS: 7.4 years)  (Figure 5A). The
13-year PFS estimates were 28.8% (median PFS: 1.9%)
and 59.1% (median PFS: not reached), for the CHOP-R
and R-HDS arms, respectively (Figure 5B). 
Rescue of patients with refractory and relapsed 
disease
Overall, 72 patients (53.7%) had disease progression (45
CHOP-R and 27 R-HDS), following partial response (PR)
or refractory disease after induction (33 patients) or recur-
rence after CR achievement (39 patients). Five patients
had progression with documented histological transfor-
mation and four with central nervous system involve-
ment. As of the last follow up, 38 (52.8%) out of 72 pro-
gressing patients were long-term survivors following sal-
vage therapies after disease recurrence. Among rescued
patients, 28 patients were in the CHOP-R and ten in the
R-HDS arms. At the last follow up, besides the 50 patients
alive in their first CR, 20 patients were long-term survivors
in their second CR (14 CHOP-R and 6 R-HDS) and 18
were surviving beyond a second CR (14 CHOP-R and 4 R-
HDS). 
High-dose therapy and autograft were employed as sal-
vage therapy in 28 patients with disease progression fol-
lowing initial CHOP-R. Nineteen of them at this follow up
were long-term survivors, with a median PFS-2 of 6.2
years. Nine patients eventually died because of lymphoma
(7 patients) or secondary malignancy (2 patients).
Allogeneic stem cell transplant was employed as the ulti-
mate rescue approach in five patients; two of them were
long-term survivors at this follow up, while three died
(one from graft-versus-host disease, one from lymphoma
progression, and one from a secondary tumor).    
Factors affecting long-term survival
In univariate analysis, the main features at disease pres-
entation and treatment end  that significantly favored
long-term survival were female sex, age <50 years, treat-
ment completion, MR and CR achievement (see Table 2).
When these factors were evaluated in multivariate analy-
sis, CR still showed a strong impact along with a border-
line value for female sex (Table 2). When PCR status
(assay performed  on 60 patients only) was excluded from
the multivariate analysis, CR was still the strongest factor
favorably affecting survival. In addition, younger age had
a strong significant impact along with female sex (Table 2).
Secondary tumor occurrence
The respective cumulative incidences of sMDS/AL at 5,
10, and 13 years were 5.9%, 8.9% and 10.5% for the 
R-HDS arm and 0.0%, 10.7%, and 10.7%, respectively,
for the CHOP-R arm (P=0.832). The respective cumulative
incidences of secondary non-MDS/AL neoplasms at 5, 10,
and 13 years were 5.9%, 10.4%, and 11.9% for the R-
HDS arm and 0%, 4.9%, and 8.8% for the CHOP-R arm
(P=0.792). Secondary neoplasms in the R-CHOP arm were
carcinomas (five total: two laryngeal, two urothelial, one
pancreatic), Hodgkin’s lymphomas (two), MDS (two total,
one of which evolved in AML), AML (one), and ALL Ph+
(one). In the R- HDS arm, we observed five carcinoma
cases (three head-and-neck, one mammary, one gastric),
one non-melanoma skin cancer, one plasma cell dyscrasia,
four MDS cases, and four AMLs.
13-year update of the R-HDS vs. CHOP-R trial in FL
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Table 2. Univariate and multivariate proportional hazard models for overall survival.
                                                                     Univariate                                       Multivariate                                           Multivariate
                                                                                                                             (with PCR)                                          (without PCR)1
                                                                 HR                     P                      HR                         P                              HR                           P
                                                            (95% CI)                                     (95% CI)                                                 (95% CI)                        
Sex                                                                        0.46                     0.019                       0.38                            0.06                                  0.43                             0.013
(F vs. M)                                                       (0.24-0.88)                                         (0.14-1.04)                                                        (0.22-0.84)                           
Age                                                                        2.21                     0.013                       2.11                           0.137                                 2.76                             0.002
(> 50 y vs. < 50 y)                                      (1.18-4.15)                                         (0.79-5.66)                                                        (1.45-5.23)                           
Spleen involvement                                         1.62                     0.109                        NA                               -                                     NA                                 -
(Yes vs. No)                                                   (0.9-2.9)                      
MRD                                                                     2.26                     0.036                       0.94                           0.919                                   -                                  -
(Pos vs.neg)                                                 (1.07-6.65)                                          (0.28-3.2)                          
Treatment completed                                     0.39                     0.002                       0.49                           0.248                                 0.56                             0.139
(Yes vs. No)                                                 (0.22-0.70)                                         (0.15-1.64)                                                        (0.26-1.22)                           
Response                                                            6.61                    <0.001                      6.79                         <0.001                               3.82                           <0.001
(no CR vs. CR)                                           (2.53-17.25)                                       (2.66-17.32)                                                       (2.12-6.89)
Arm                                                                       1.21                     0.524                        NA                               -                                     NA                                 -
(R-HDS vs. CHOP-R)                                 (0.68-2.17)                                                   
HR: Hazard Ratio; CI: Confidence Interval; MRD: minimal residual disease; F: female; M: male; y: years; Pos.: positive; neg.: negative; CR: complete remission; R-HDS: high-dose
chemotherapy with rituximab and autograft; CHOP-R: conventional chemotherapy with rituximab. 1Polymerase chain reaction (PCR) data are available for a subgroups of 60
patients. NA: not included in the analysis. 
Discussion
The present study reports outcomes after a median 13
years of follow up of a multicenter prospective trial compar-
ing high-dose chemotherapy and autograft versus CHOP
chemotherapy, both delivered with rituximab (R-HDS vs.
CHOP-R), as upfront therapy in high-risk FL patients. To
our knowledge, this follow up is the longest ever reported
for first-line treatment of FL with rituximab-supplemented
chemotherapy. The prolonged observation shows an
extraordinary improvement in OS compared to the pre-rit-
uximab era.15,16 The survival was similar in both treatment
arms, confirming over the long-term our preliminary obser-
vation that R-HDS does not add survival advantages com-
pared to CHOP-R in the upfront therapy of high-risk FL.9
CR achievement was the most important factor for pro-
longed survival. The importance of disease response is fur-
ther emphasized by the first-time observation that MR
achievement is associated with survival duration and a high
proportion of patients had prolonged survival in the
absence of disease recurrence.
The GITMO-IIL trial was designed for patients with
high-risk FL, histologically diagnosed according to the
Revised European-American Classification of Lymphoid
Neoplasms (REAL)/World Health Organization (WHO)
lymphoma classification.14 The FL diagnosis was confirmed
by the high rate of BCL-2 gene translocation detected in
patients with molecular assessment. The high-risk presen-
tation was proved using the clinical prognostic scores avail-
able when the protocol was designed.15-16 The subsequently
developed FLIPI score employs other clinical parameters,
and a proportion of our patients were not true “high risk”
according to FLIPI.28 Nevertheless, all study patients clearly
belonged to a severely ill population, with a 5-year survival
expectancies of 43.6% (age-adjusted IPI score) and 38%
(Italian Lymphoma Intergroup score), according to treat-
ment available at the time the trial was conceived.15,16 The
13-year survival of 66.4% recorded in our series represents
a marked improvement in life expectancy compared to sur-
vival reported in the pre-rituximab era for similar high-risk
FL patients. This result is especially notable because only
four rituximab doses were applied to the majority of
patients, and the treatment schedule was not that most fre-
quently delivered in present times. 
Recently, two other prospective trials performed in
advanced-stage FL with rituximab-based upfront regimens
have been updated: the Italian FOLL05 study comparing R-
CVP, R-CHOP, and R-FM and the SWOG study comparing
R-CHOP versus CHOP followed by radioimmunothera-
py.29,30 Both the FOLL05 study, with 8-year OS of 83%, and
the SWOG study, with 10-year OS of 78%, showed
extended life expectancies in the absence of rituximab
maintenance. These values are in line with our 13-year OS
of 66% obtained in a selected group of high-risk FL. The
results strengthen the observations from several retrospec-
tive studies showing prolonged survival in FL following
immunochemotherapy.10-13 Moreover, results from all of
these studies indicate that the CHOP schedule delivered
R. Bruna et al.
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Figure 4. Updated disease-free survival (DFS) according to treatment arms.
Intensive chemo-immunotherapy with autograft (R-HDS) vs. conventional
chemoimmunotherapy (CHOP-R). No: number; yrs: years.
Figure 5. Updated event-free survival (EFS) and progression-free survival (PFS) according to treatment arms. Intensive chemoimmunotherapy with autograft (R-HDS)
versus conventional chemoimmunotherapy (CHOP-R). (A)  EFS. (B) PFS. No: number; yrs: years.
A B
with rituximab is currently the first choice for the upfront
treatment of advanced stage FL, ensuring prolonged sur-
vival, with adequate information about possible late side
effects. 
In our whole series, lymphoma progression remained the
most frequent cause of failure, accounting for 47.8% of all
causes of death. This is in line with several previous obser-
vations, including a recent report on a large series of FL.31
Indeed, lymphoma progression was much more often
responsible for fatal outcome among patients allocated to
the CHOP-R arm, with 65% of all deaths, compared to the
R-HDS arm with only 35% of all deaths. On the other
hand, early and late toxicities were the most frequent cause
of failure for patients in the R-HDS arm, which counterbal-
anced the increased anti-lymphoma activity of R-HDS
compared to CHOP-R, resulting in analogous overall sur-
vival for the two treatment arms. Rituximab maintenance is
now used with the aim of reducing disease recurrence risk.32
In addition, both bendamustine and the novel anti-CD20
obinutuzumab antibody have been proposed as more effec-
tive first-line treatments compared to R-CHOP.33,34 In partic-
ular, bendamustine is now frequently used as first-line
treatment in place of the CHOP schedule. However, no evi-
dence is currently available to suggest that these novel treat-
ment strategies will substantially reduce the risk for dis-
ease-related deaths without affecting the treatment safety
profile in the long term. Indeed, our update reinforces the
need for prolonged observation to define the true survival
advantage of any novel treatment for FL. Novel treatments
for FL should combine potent anti-lymphoma activity along
with low risk of both early and late toxicities.
Most late toxicities were secondary malignancies associ-
ated with the use of high-dose therapy with autograft deliv-
ered either upfront in the R-HDS arm or as salvage therapy
in a good proportion of patients failing after upfront CHOP-
R. This finding is in line with previous reports, including a
retrospective study from the Gruppo Italiano Terapie
Innovative nei Linfomi (GITIL) group indicating increased
risk for secondary MDS/AL in lymphoma patients receiving
high-dose therapy and autograft.35 A recent surveillance
study by the Spanish Lymphoma Group (GELTAMO)
group has further stressed the risk of secondary MDS/AL in
FL patients undergoing autograft.36 Moreover, both the
GITIL and GELTAMO studies indicated a trend for
increased risk for secondary solid tumors when autograft is
delivered along with rituximab.35,36 Thus, the risk for late
occurrence of secondary malignancy is a main issue in the
long-term management of FL patients. This concern must
be kept in mind in the long-term assessment of the efficacy
of novel drugs and drug combinations.33,34,37-39 
The present study allows identification of the factors
favoring the long-term survival of high-risk FL patients
treated with rituximab-containing chemotherapy.
Somewhat unexpectedly, CR achievement proved to be the
strongest prerequisite for long-term survival. Several recent
observations indicate that response to initial treatment
along with the achievement of a strong and durable
response may favorably affect long-term outcome.31,40-44 The
present update clearly demonstrates in a prospective study
that CR achievement shows the strongest association with
prolonged survival. The importance of the response depth
for long-term survival is confirmed by our molecular moni-
toring of measurable residual disease (MRD) performed in
a subset of patients. Most studies have shown a remarkable
prognostic value of MRD assessment in terms of PFS and
response duration.9,17,20,45,46 Nevertheless, the impact on OS
could not be fully addressed in most studies, usually
because of inadequate follow up.47,48 Here, it was possible to
demonstrate for the first time that MRD assessment is pre-
dictive for both PFS and OS, and that MR was associated
with a prolonged survival. 
The association of response depth with long-term sur-
vival in our FL series is further substantiated by the obser-
vation that a good proportion of patients (approx. 37% of
the whole series) could survive in their first CR at long term.
The DFS curves were definitely promising, with a 13-year
estimate as high as 65% in R-HDS-treated patients.
Moreover, most patients achieving MR following induction
treatment maintained their MR during long-term molecular
monitoring. Taken together, these results indicate that an
extensive disease response in FL may translate into both
prolonged survival and in the long-term persistence of CR;
a state that has been described as functional cure in other
clinical settings. This in turn raises the issue of the curability
of FL, at least in patients with a high-risk clinical presenta-
tion such as those selected in the present study.
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